3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
20
Carcinoma, Renal Cell
16
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Endometrial Neoplasms
7
Neoplasms
4
Biliary Tract Neoplasms
4
Uterine Cervical Neoplasms
3
Neuroendocrine Tumors
3
Melanoma
3
Liver Neoplasms
3
Vulvar Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
von Hippel-Lindau Disease
1
Thyroid Carcinoma, Anaplastic
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Penile Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Lung Neoplasms
1
Kidney Neoplasms
1
Interventions
Cisplatin
14
Paclitaxel
12
pembrolizumab
9
Fluorouracil
7
Radiotherapy
6
Irinotecan
5
Esophagectomy
5
tislelizumab
4
Oxaliplatin
4
Leucovorin
4
Drug Therapy
4
Carboplatin
4
toripalimab
3
Levoleucovorin
3
Docetaxel
3
Capecitabine
3
camrelizumab
2
Taxes
2
Radiation
2
Nivolumab
2
Injections
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
sintilimab
1
palbociclib
1
nimotuzumab
1
nazartinib
1
lenvatinib
1
ivarmacitinib
1
futibatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Squamous Cell Carcinoma
×
lenvatinib
×
90 days
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled